Collins Helen Louise's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Sep 21, 2026
- Accession no.
- 0001701247-26-000013
- Filed
- Sep 21, 2026, 5:22 PM ET
- Trade date
- Sep 17, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $251.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Collins Helen LouiseCIK 0001701247 | Officer (CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Common Stock | MOption exerciseAcquired | +5,000 | $2.48 | +$12,400 | 30,000 | Direct | |
| Sep 17, 2026 | Common Stock | SSaleDisposed | −2,916 | $50.03F3 | −$145,890.98 | 27,084 | Direct | |
| Sep 17, 2026 | Common Stock | SSaleDisposed | −1,844 | $50.71F4 | −$93,507.21 | 25,240 | Direct | |
| Sep 17, 2026 | Common Stock | SSaleDisposed | −240 | $51.48F5 | −$12,355.68 | 25,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 106,268 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $49.305 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $50.3099 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $51.365 to $51.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.